The promise and dangers of editing the genome of a human embryo are being discussed by scientists around the world. They are contemplating whether it should be allowed or not— and if so, under what...
Vedanta raises USD 27 Million to move microbiome assets through the clinic Vedanta Biosciences raises USD 27 million in its series C round. The cash will bolster its microbiome-derived drugs pipeline. The capital will aid a phase 1/2 trial of VE416 in food allergy, a phase 2 study of VE303 in recurrent...
Find More
In a groundbreaking clinical trial, a 66-year-old Ohio woman became the first patient to become cancer free through the CAR T Cell Therapy. In August this year, Denise Kennan had participated in the cancer treatment trial at the Seidman Cancer Center in University Hospitals of Cleveland; following which 30 days late...
Find More
Chinese scientist - He Jiankui’s extraordinary claim regarding making the first babies — twin girls — with edited genomes astonished the world. Among researchers’ principal concerns are the potential effects of the genetic alterations on the health of girls. He, a genome-editing researcher at the Southern University...
Find More
The world of cancer cells is bewildering, very difficult in understanding. The behaviour of cancer cells is not only complex but also intriguing. Research has been unfolding mystery after mystery of the complex world of cancer cells, shedding more and more light into the mysterious nature of cancer cells. In a new t...
Find More
The researchers announced that they had edited human embryos to repair a damaged gene that can lead to heart failure, but critics raised their eyebrows. Now, new evidence confirms that the gene editing was successful, said by reproductive and developmental biologist Shoukhrat Mitalipov of Oregon Health & Science...
Find More
Preclinical biotech Synthorx needs a USD 100 Million IPO The early-stage Synthorx needs USD 100 million IPO. A while ago, La Jolla, California-based biotech got off a USD 63 million series C, but now wants a USD 100 million from an IPO to progress its pipelines of synthetic cytokines, which are designed to improve ...
Find More
Gilead remunerates USD 50 Million to collaborate with synthetic lethality startup Tango Gilead is remunerating USD 50 million upfront to enter into an immuno-oncology collaboration with Massachusetts-based Tango Therapeutics. The deal provides Gilead with the option to receive the worldwide rights to five targets d...
Find More
Novartis signs USD 2.1Billion for Endocyte acquisition Novartis has inked USD 2.1 billion agreement to takeover Endocyte. Endocyte, a biopharmaceutical company, headquartered in Indiana, licensed the cancer drug that catches Novartis’ eye for USD 12 million. Endocyte was in the stagnation when it held its recovery h...
Find More
Gene Therapy is now touted as a new revolution for cancer treatment. If the list of new cancer treatment methodologies is traversed, then the end seems to be farther and farther away. As a sequel to the relentless efforts by researchers across the world to formulate therapies better than the existing ones, new prosp...
Find More
Lamellar Ichthyosis (LI) is an autosomal recessive congenital Ichthyosis (ARCI), which mainly affect.....
Find More
Affecting the entire body, Adult Onset Still's disease (AOSD) is a rare type of inflammatory arthrit.....
Find More
The convergence of technologies and the increasing integration of medical devices to computer networ.....
Find More
Cocaine Use Disorder (CUD) is characterized as a substance use disorder in which biological, psychol.....
Find More
T cell Lymphoma (TCL) is cancer that develops in the T-lymphocytes. T-cell Lymphomas are majorly cla.....
Find More
Alzheimer's disease is an irreversible, progressive disorder of the brain that progressively destroy.....
Find More-Agonist.png "Toll-like Receptors Agonist")
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.
